Melanotan II research, identity and evidence limits
Melanotan II is a cyclic melanocortin-receptor agonist investigated for pigmentation and other effects. A very small human pilot does not establish a safe cosmetic tanning treatment.
Identity and formulation
The original study identifies a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. It is different from afamelanotide and bremelanotide.
A shared melanocortin target does not make approved products containing related molecules interchangeable with Melanotan II.
What the studies show
The directly reviewed human evidence consists of an early phase-I pilot with three volunteers and a later adverse-event case report. This combination provides a preliminary signal of biological activity and reasons for caution, not a reliable benefit-risk estimate for broad use.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.
Single-blind pilot phase-I study in three male volunteers Reading scope: PubMed bibliographic record and abstract |
The study observed pigmentation changes in two participants, alongside nausea, fatigue or somnolence and spontaneous erections. | The sample was extremely small and the exposure brief; it could not characterize uncommon harms or long-term effects. |
| Melanotan II: a possible cause of renal infarction: review of the literature and case report.
Clinical case report with a literature discussion Reading scope: PubMed bibliographic record and abstract |
The report describes renal infarction considered possibly related to Melanotan II exposure. | A case report cannot establish causation or incidence, and should not be presented as a controlled risk estimate. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
How to interpret the findings
Pigmentation is a measurable effect, but it is not evidence of protection from ultraviolet injury or a favorable long-term cosmetic safety profile.
The tiny pilot and later safety signal answer different questions. Neither should be omitted: a possible benefit signal is not a safety guarantee, and a case association is not proof that every exposure causes the event.
Safety context
The early trial documented unwanted effects even during short observation. The renal case adds a serious reported concern while leaving causality uncertain.
The material and exposure in an online product may differ from the characterized research preparation, adding another uncertainty to any comparison.
Study exposure and units
The escalation in the three-person phase-I experiment was an exploratory research procedure, not a validated cosmetic regimen. This profile deliberately does not translate it into personal-use instructions.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Product identity and report checks
Resolve whether the material is Melanotan II, afamelanotide or bremelanotide. Require an identity method able to support the specific cyclic peptide claimed, rather than a generic melanotan name.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
Common questions
Does Melanotan II approval follow from Scenesse or Vyleesi?
No. Those names refer to different molecules and specific prescription formulations. Their evidence cannot be transferred simply because all involve melanocortin signaling.
Can a tanning response establish protection from sun damage?
No. The pilot measured pigmentation, not prevention of skin cancer or a validated substitute for sun protection.
Does the renal report prove a predictable rate of kidney injury?
No. It is an individual clinical observation. It is important for safety review but cannot quantify how commonly such an event occurs.
Sources
- Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. (PubMed bibliographic record and abstract)
- Melanotan II: a possible cause of renal infarction: review of the literature and case report. (PubMed bibliographic record and abstract)